About Compeed
Compeed is Europe's best-selling blister plaster brand, developed in 1984 by Lars Backsell while working for Danish company Coloplast. The name is a contraction of "Competition" and "Seed," reflecting its athletic applications. Originally designed for treating ostomy patients, the hydrocolloid technology was adapted for consumer use after a successful 1984 clinical trial with the Swedish army. First sold in Sweden in 1986, Compeed quickly established itself as the leading blister treatment solution. The hydrocolloid gel technology creates a protective, cushioning barrier that relieves pain immediately while maintaining optimal moisture levels to promote natural healing. This medical-grade technology, originally developed for wound care, set Compeed apart from traditional plasters. The brand has had several owners over its history. Sold to Johnson & Johnson in May 2002, Compeed grew significantly in value over 15 years before being acquired by French pharmaceutical company HRA Pharma in September 2017 for approximately $1 billion. In 2022, HRA Pharma was acquired by Perrigo Company plc, though manufacturing remains with Coloplast in Denmark. Today, Compeed offers a comprehensive range of hydrocolloid plasters for blisters (including specific designs for heels and toes), corns, cracked heels, and cold sores. The brand has partnerships with athletic organisations worldwide, including USA Triathlon, reinforcing its reputation as the trusted choice for athletes and active individuals.








